iKena says ISS, Glass Lewis recommends stockholders vote for merger
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 11 2025
0mins
Merger Recommendation: Ikena Oncology has received recommendations from Institutional Shareholder Services and Glass, Lewis & Co. to vote in favor of the share issuance related to its proposed merger with Inmagene Biopharmaceuticals at the upcoming Annual Meeting on July 15, 2025.
Inmagene Overview: Inmagene is a clinical stage biopharmaceutical company developing IMG-007, an engineered monoclonal antibody designed to reduce safety risks and allow for less frequent dosing.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
